(Q37876420)

24 August 2017

1 reference

title

HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation (English)

1 reference

24 August 2017

0 references

0 references

José Augusto Nogueira-Machado

1

1 reference

24 August 2017

Caroline Maria de Oliveira Volpe

2

1 reference

24 August 2017

Clara Araujo Veloso

3

1 reference

24 August 2017

Miriam Martins Chaves

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

17 May 2011

1 reference

Expert Opinion on Therapeutic Targets

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1023-1035

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

TLR4 and Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Is type II diabetes mellitus a disease of the innate immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Fat meets the cholinergic antiinflammatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

HMGB1: endogenous danger signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Hmgb-1 as a therapeutic target for infectious and inflammatory disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High glucose induces toll-like receptor expression in human monocytes: mechanism of activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

HMGB proteins and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

HMG1 and 2: architectural DNA-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The extracellular release of HMGB1 during apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

HMGB1 is an endogenous immune adjuvant released by necrotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Upregulation of RAGE and its ligands in proliferative retinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High mobility group box 1 protein interacts with multiple Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High mobility group box-1 recognition: the beginning of a RAGEless era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Recombinant HMGB1 with cytokine-stimulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

HMGB1 develops enhanced proinflammatory activity by binding to cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Native versus recombinant high-mobility group B1 proteins: functional activity in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Type 2 diabetes mellitus: a disease of the innate immune system? An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

An immune origin of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptors in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

TLR4 links innate immunity and fatty acid-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Current views of toll-like receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

MyD88, an adapter protein involved in interleukin-1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

MyD88: an adapter that recruits IRAK to the IL-1 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Experimental evidence for a metallohydrolase mechanism in which the nucleophile is not delivered by a metal ion: EPR spectrokinetic and structural studies of aminopeptidase from Vibrio proteolyticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Murine retroviruses activate B cells via interaction with toll-like receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The apoptotic signaling pathway activated by Toll-like receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for advanced glycation end product-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Septic shock is associated with receptor for advanced glycation end products ligation of LPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE: a novel cellular receptor for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Central role of RAGE-dependent neointimal expansion in arterial restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.575360

10.1517/14728222.2011.575360

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference